TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q4 2021
Holdings as of Dec 31, 2021, filed Feb 18, 2022. Long positions only.
- Positions
- 15
- No filing for Q3 2021
- Portfolio value
- $213.6M
- No filing for Q3 2021
TCG Crossover Management, LLC did not file a 13F for Q3 2021, so these holdings cannot be compared with the previous quarter and changes are not shown.
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ISEEIVERIC bio, Inc. | COM | 1,741,228 | $29.1M | 13.6% | – | – | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,314,000 | $26.0M | 12.2% | – | – | History |
| COGTCogent Biosciences, Inc. | COM | 2,750,037 | $23.6M | 11.0% | – | – | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 5,905,400 | $20.0M | 9.3% | – | – | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 1,170,212 | $16.2M | 7.6% | – | – | History |
| ACRSAclaris Therapeutics, Inc. | COM | 1,082,213 | $15.7M | 7.4% | – | – | History |
| KDNYChinook Therapeutics, Inc. | COM | 882,353 | $14.4M | 6.7% | – | – | History |
| TYRATyra Biosciences, Inc. | COM | 850,450 | $12.0M | 5.6% | – | – | History |
| TRDAEntrada Therapeutics, Inc. | COM | 663,694 | $11.4M | 5.3% | – | – | History |
| JBIOJade Biosciences, Inc. | COM | 853,330 | $10.1M | 4.7% | – | – | History |
| DNTHDianthus Therapeutics, Inc. | COM | 2,222,222 | $9.84M | 4.6% | – | – | History |
| AKUSAkouos, Inc. | COM | 1,045,215 | $8.88M | 4.2% | – | – | History |
| MRUSMerus N.V. | COM | 225,000 | $7.16M | 3.4% | – | – | History |
| ZLABZai Lab Ltd | ADR | 95,000 | $5.97M | 2.8% | – | – | History |
| ELEVElevation Acquisition Group Inc. | COM | 555,000 | $3.34M | 1.6% | – | – | History |